Fundraising Fox

ARMR Sciences

New York, US · Founded 2023 · Delaware corporation · 1 known investors

ARMR Sciences is developing conjugate vaccines and biologic countermeasures, including its lead candidate ARMR-100, designed to bind fentanyl in the bloodstream and prevent overdose from synthetic drugs. It targets high-risk populations such as first responders, military personnel, and individuals in recovery, working on a platform approach to address emerging drug threats.</parameter> <parameter name="sector_codes">["biotech", "healthtech", "deeptech"]

BiotechDeep TechHealthtech

Founders & leadership

ARMR Sciences was founded in 2023 by David Dowling.

DD
David DowlingFounder
SR
Shon RemichNamed on SEC filing
JHJeffrey Hwang
Jeffrey HwangNamed on SEC filing
NJNicholas Jacob
Nicholas JacobNamed on SEC filing
CGCollin Gage
Collin GageNamed on SEC filing
KKKenneth Kohn
Kenneth KohnNamed on SEC filing
DSDenise Shull
Denise ShullNamed on SEC filing

Investors · 1

Daft CapitalPalo Alto · $500K – $2Mvia Jon Dishotsky · inferred

Reported raises · per SEC filings

Form D private placements
▶$30MofferedAug 2025 · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Shon RemichExecutive Officer
  • Jeffrey HwangDirector
  • Nicholas JacobExecutive Officer
  • Collin GageExecutive Officer, Director
  • Kenneth KohnDirector
  • Denise ShullDirector
Offering amount
$30M
Minimum investment
$5K
Placement agents
Digital Offering, LLC
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Aro Biotherapeutics11 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Companies competing with ARMR Sciences for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

BioMedNewsBreaks — ARMR Sciences Inc. Advances Fentanyl Vaccine with Private Placement Led by Joseph Gunnar & Co.streetinsider.com · Apr 2026ARMR Sciences has filed a notice of an exempt offering of securities to raise $30 Million in New Funding. - intelligence360intelligence360.news · Sep 2025ARMR Launches up to $30M Capital Raise | citybizcitybiz.co · Aug 2025$30M Capital Raise: ARMR Develops AI-Powered Fentanyl Prevention Biodefense | ARMR Stock Newsstocktitan.net · Aug 2025ARMR Launches up to $30M Capital Raise to Advance Biodefense Platform Against Fentanyl and AI-Driven Synthetic Drug Threatsfinance.yahoo.com · Aug 2025Expanded Access Policy | ARMR Sciencesarmrsciences.com · Sep 2024

Frequently asked questions

What does ARMR Sciences do?
ARMR Sciences is developing conjugate vaccines and biologic countermeasures, including its lead candidate ARMR-100, designed to bind fentanyl in the bloodstream and prevent overdose from synthetic drugs. It targets high-risk populations such as first responders, military personnel, and individuals in recovery, working on a platform approach to address emerging drug threats.</parameter> <parameter name="sector_codes">["biotech", "healthtech", "deeptech"]
Who founded ARMR Sciences?
ARMR Sciences was founded by David Dowling in 2023.
Who are ARMR Sciences's investors?
ARMR Sciences's investors include Daft Capital.
Where is ARMR Sciences headquartered?
ARMR Sciences is headquartered in New York, US.